A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneoulsy Administered ELX-02 in Patients with Cystic Fibrosis with at Least One G542X Allele.

  • Wilson, John (Primary Chief Investigator (PCI))
  • Burr, Lucy D. (Chief Investigator (CI))
  • Morton, Judith M. (Chief Investigator (CI))
  • Visser, Simone K. (Chief Investigator (CI))

Project: Research

Project Details

StatusFinished
Effective start/end date1/02/21 → 31/12/24

Keywords

  • Respiratory medicine
  • Cystic fibrosis
  • Clinical trial

Clinical Trial Phase

  • Phase II